Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Sep;54(2):167-77.
doi: 10.1023/a:1012965617685.

Endocrine inactive and gonadotroph adenomas: diagnosis and management

Affiliations
Review

Endocrine inactive and gonadotroph adenomas: diagnosis and management

M Losa et al. J Neurooncol. 2001 Sep.

Abstract

Endocrine inactive pituitary adenomas represent about one quarter of all pituitary tumors. By immunocytochemistry, most of these tumors are positive for intact gonadotropins and/or their subunits. Clinical presentation is usually secondary to mass effect symptoms, such as visual disturbances, headache, and hypopituitarism. Differential diagnosis is usually accomplished by neuroradiologic studies, even though in selected cases positron emission tomography and/or single photon emission tomography may aid to distinguish pituitary adenomas from other endocrine inactive lesions, such as meningiomas and craniopharyngiomas. Surgical management is usually considered the first choice treatment for patients with endocrine inactive pituitary adenomas because it is very effective in ameliorating symptoms of chiasmal compression and headache. Radical removal of the tumor, however, is difficult to obtain because of the frequent invasiveness into the cavernous sinus. Radiation therapy diminishes the likelihood of tumor recurrence, especially in patients with demonstrable tumor remnants after surgery. Medical therapy with dopaminergic drugs, somatostatin analogs, or gonadotropin-releasing hormone agonists or antagonists causes mild reduction of tumor size in few patients and, therefore, seems to be of limited value in the therapeutic management of patients with endocrine inactive pituitary adenomas.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Acta Endocrinol (Copenh). 1983 Feb;102(2):167-72 - PubMed
    1. Acta Endocrinol (Copenh). 1993 Jul;129 Suppl 1:21-6 - PubMed
    1. J Clin Endocrinol Metab. 1989 Jan;68(1):81-6 - PubMed
    1. Baillieres Clin Endocrinol Metab. 1995 Apr;9(2):367-89 - PubMed
    1. J Clin Endocrinol Metab. 1991 Oct;73(4):850-6 - PubMed

Substances

LinkOut - more resources